Trial · NCT03000179
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate as Measured Using RECIST 1.1 | Avelumab Monotherapy | 0.29 | 95% Confidence Interval 0.08 to 0.64 | proportion of participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Anemia, Grade 1 | 2 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Fatigue, Grade2 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Infusion related reaction. Grade2 | 2 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Alanine aminotransferase increased, Grade 1 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Alkaline phosphatase increased, Grade 1 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Anorexia, Grade 2 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Blood bilirubin increased, Grade1 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Diarrhea, Grade 1 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Diabetic ketoacidosis, Grade 4 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Back pain, Grade 1 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Diverticulitis per upper GI series, Grade 2 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Hypokalemia, Grade 3 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Hyponatremia, Grade 3 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Nausea, Grade 2 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Rash maculo-papular, Grade 1 | 1 | Participants | |
| Number of Patients With Each Worst-Grade Toxicity | Avelumab Monotherapy | Urticaria, Grade 1 | 1 | Participants | |
| Overall Survival | Avelumab Monotherapy | 6.4 | 95% Confidence Interval 3.8 to NA | months | |
| Progression Free Survival | Avelumab Monotherapy | 3.4 | 95% Confidence Interval 3.0 to NA | months | |
| Duration of Response | Avelumab Monotherapy | 10.9 | Full Range 3.0 to 18.8 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03000179/results